Literature DB >> 9084068

The ability of THA treatment to increase cortical alpha waves is related to apolipoprotein E genotype of Alzheimer disease patients.

P Riekkinen1, H Soininen, J Partanen, A Pääkkönen, S Helisalmi, P Riekkinen1.   

Abstract

In a previous study, we reported that Alzheimer disease (AD) patients with an apolipoprotein E (APOE) epsilon 4 allele (+ APOE4) show more severe loss of nucleus basalis (NB) cholinergic cells than patients without epsilon 4 alleles (-APOE4). The present study investigates the effects of a single oral administration of THA 25 or 50 mg on cortical spectral EEG activity in + (five APOE4/4, six APOE4/3) and -APOE4 (eight APOE3/3) AD patients. THA 25 mg had no significant effect on EEG activity in any AD patients. However, THA 50 mg increased alpha activity and alpha/theta ratio in -APOE4 patients. In contrast, THA 50 mg had no effect on EEG activity in + APOE4 patients. This result tentatively suggests that in AD patients APOE genotype may affect the response of cortical electrical arousal to cholinergic therapy that enhances the efficacy of presynaptic NB axons.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9084068     DOI: 10.1007/s002130050192

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  Memory functions in human subjects with different apolipoprotein E phenotypes during a 3-year population-based follow-up study.

Authors:  E L Helkala; K Koivisto; T Hanninen; M Vanhanen; K Kervinen; J Kuusisto; L Mykkanen; Y A Kesaniemi; M Laakso; P Riekkinen
Journal:  Neurosci Lett       Date:  1996-02-09       Impact factor: 3.046

Review 2.  The cholinergic system and EEG slow waves.

Authors:  P Riekkinen; G Buzsaki; P Riekkinen; H Soininen; J Partanen
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1991-02

3.  Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E epsilon 4 allele.

Authors:  H Soininen; K Partanen; A Pitkänen; M Hallikainen; T Hänninen; S Helisalmi; A Mannermaa; M Ryynänen; K Koivisto; P Riekkinen
Journal:  Neurology       Date:  1995-02       Impact factor: 9.910

4.  Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco-EEG in patients with Alzheimer's disease.

Authors:  K Alhainen; J Partanen; K Reinikainen; V Laulumaa; H Soininen; M Airaksinen; P Riekkinen
Journal:  Neurosci Lett       Date:  1991-06-10       Impact factor: 3.046

5.  Effects of THA on passive avoidance retention performance of intact, nucleus basalis, frontal cortex and nucleus basalis + frontal cortex-lesioned rats.

Authors:  P Riekkinen; J Sirviö; M Riekkinen; P Riekkinen
Journal:  Pharmacol Biochem Behav       Date:  1991-08       Impact factor: 3.533

6.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain.

Authors:  P J Whitehouse; D L Price; R G Struble; A W Clark; J T Coyle; M R Delon
Journal:  Science       Date:  1982-03-05       Impact factor: 47.728

7.  A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

Authors:  K L Davis; L J Thal; E R Gamzu; C S Davis; R F Woolson; S I Gracon; D A Drachman; L S Schneider; P J Whitehouse; T M Hoover
Journal:  N Engl J Med       Date:  1992-10-29       Impact factor: 91.245

8.  Effect of alpha2 antagonists and an agonist on EEG slowing induced by scopolamine and lesion of the nucleus basalis.

Authors:  P Riekkinen; J Sirviö; P Jäkälä; R Lammintausta; P Riekkinen
Journal:  Neuropharmacology       Date:  1990-11       Impact factor: 5.250

Review 9.  Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease.

Authors:  J Poirier
Journal:  Trends Neurosci       Date:  1994-12       Impact factor: 13.837

10.  Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein.

Authors:  T Polvikoski; R Sulkava; M Haltia; K Kainulainen; A Vuorio; A Verkkoniemi; L Niinistö; P Halonen; K Kontula
Journal:  N Engl J Med       Date:  1995-11-09       Impact factor: 91.245

View more
  1 in total

Review 1.  The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems.

Authors:  A D Lawrence; B J Sahakian
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.